FIGURE 8:

Inhibition of ALK1/2/3/6 specifically reduces proliferation of Cav1* patient fibroblasts. (A) Fibroblasts were treated with LDN193189, an inhibitor of ALK1/2/3/6, for 24 h, and the proliferation rate of fibroblasts was determined. LDN193189 (1 μM) significantly reduced proliferation of Cav1* fibroblasts to the level of WT cells at baseline. In contrast, WT fibroblast proliferation was not altered by LDN193189. (B) Experiments were also made using SB431542, an inhibitor of ALK4/5/7, which induced similar reductions in WT and Cav1* fibroblast proliferation.